Amnon Amit1, Orit Person, Zohar Keidar. 1. Department of Obstetrics and Gynecology, Gynecologic Oncology Unit, Rambam Healthcare Campus, Haifa, Israel. a_amit@rambam.health.gov.il
Abstract
PURPOSE OF REVIEW: To evaluate the role of fluorodeoxyglucose (FDG) PET/CT as cancer response testing in gynecological malignancies. RECENT FINDINGS: The application of FDG PET/CT in patients with endometrial and ovarian cancer to evaluate treatment response was found to have no clinical benefits.Patients with cervical cancer seem to benefit from the use of PET/CT in estimation of treatment response. The influence of different treatments on FDG uptake, timing, frequency of examination, and survival advantage are evaluated and discussed. SUMMARY: Growing evidence supports an important role for functional imaging FDG PET/CT as a monitoring tool in patients with uterine-cervix carcinoma. Further studies are needed to establish the clinical benefits of this modality in this population.
PURPOSE OF REVIEW: To evaluate the role of fluorodeoxyglucose (FDG) PET/CT as cancer response testing in gynecological malignancies. RECENT FINDINGS: The application of FDG PET/CT in patients with endometrial and ovarian cancer to evaluate treatment response was found to have no clinical benefits.Patients with cervical cancer seem to benefit from the use of PET/CT in estimation of treatment response. The influence of different treatments on FDG uptake, timing, frequency of examination, and survival advantage are evaluated and discussed. SUMMARY: Growing evidence supports an important role for functional imaging FDG PET/CT as a monitoring tool in patients with uterine-cervix carcinoma. Further studies are needed to establish the clinical benefits of this modality in this population.
Authors: Marcelo A Queiroz; Rahel A Kubik-Huch; Nik Hauser; Bianka Freiwald-Chilla; Gustav von Schulthess; Johannes M Froehlich; Patrick Veit-Haibach Journal: Eur Radiol Date: 2015-05-29 Impact factor: 5.315